New Study published showing Nevisense impact on clinician confidence and accuracyJanuary 26, 2022
STOCKHOLM, SWEDEN, - January 26, 2022 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today that a new study supporting the use of Nevisense in diagnosing melanoma has been published in "SKIN - The journal of cutaneous medicine". The article is authored by Avani Kolla, Prof David Polsky and others from The Ronald O. Perelman Department of Dermatology, NYU Grossman School of Medicine in New York. The study shows that Nevisense provides valuable diagnostic guidance when evaluating atypical pigmented skin lesions.
SciBase announces a change in the Management team and new head of Quality and Regulatory Affairs.January 19, 2022
SciBase has appointed Alf Laurell as Director of Quality Assurance and Regulatory Affairs and Person for Regulatory Compliance (PRRC) for SciBase. Alf joins SciBase from Elekta in Stockholm. The previous head of Quality and Regulatory and PRRC, Niklas Jakobsson has decided to pursue a new opportunity outside the company and as such leaves the SciBase Management team.
SciBase submits request for payment rate to NGSDecember 22, 2021
STOCKHOLM, SWEDEN, - December 22, 2021 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today that a request for an appropriate Medicare payment assignment for the Nevisense procedure has been submitted to "National Government Services" (NGS), the Medicare Administrative Contractor with carrier jurisdiction responsibility for New York and several other states.
- Load more news...